Moderna posted fourth quarter earnings that surpassed expectations. The pharma company also boosted its full-year revenue outlook for Covid vaccine sales.
and unveiled a new $3 billion share repurchase plan.
Moderna’s diluted GAAP earnings came in at $11.29 per share for the three months ending in December, beating the Street expectations of $9.90 per share. It incurred a loss of -69 cents per share loss in the year-ago quarter.
Revenues of $7.21 billion also exceeded analysts' estimates.
Looking ahead, the company projects sales of its mRNA-1273 coronavirus vaccine, Spikevax , in the region of $19 billion for the year 2022, with additional signed options of approximately $3 billion.
Moderna said that orders have also been confirmed for 2023 from Canada, the United Kingdom and Taiwan.